SIGA’s strategy is focused on delivering long-term shareholder value. To achieve this, the Company has concentrated its efforts in four pivotal areas to drive growth. These priorities include continuing our partnership with the U.S. Government, advancing regulatory approvals for TPOXX in new indications and formulations, cultivating strategic partnerships to expand global access to TPOXX, and leveraging our capabilities to move into complementary therapeutic areas.
For more information, please see SIGA’s management presentation.